Cardiosense says its CardioTag device is the first wearable sensor that simultaneously captures high-fidelity ECG, PPG and SCG signals ...

"Pharmacotherapy can help people living with obesity improve overall health, not just lose weight," says Dr. Sue D. Pedersen, ...

There is lower risk for recurrent HF hospitalization in older patients that receive SGLT2is following acute decompensated heart failure.

After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in ...

Left bundle branch block may serve as an important indicator for asymptomatic individuals predisposed to heart failure.

Key Points GAAP revenue surged to $66.8 million in Q2 2025, driven by recognition of one-time license and milestone payments, exceeding analyst estimates by 3,065.9% (GAAP). GAAP loss per share ...

TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease ...

US-based Cardurion Pharmaceuticals has completed enrolment in two multi-centre, global Phase II CYCLE trials of the ...

Early symptoms like fatigue, breathlessness, swelling mimic common heart issues, causing cardiac amyloidosis to go undetected ...

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...